Insider Selling: Evolent Health Inc (EVH) COO Sells 70,000 Shares of Stock

Evolent Health Inc (NYSE:EVH) COO Thomas Peterson III sold 70,000 shares of the company’s stock in a transaction dated Thursday, September 13th. The shares were sold at an average price of $27.50, for a total transaction of $1,925,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Thomas Peterson III also recently made the following trade(s):

  • On Thursday, August 30th, Thomas Peterson III sold 30,000 shares of Evolent Health stock. The shares were sold at an average price of $25.00, for a total transaction of $750,000.00.
  • On Monday, July 2nd, Thomas Peterson III sold 10,000 shares of Evolent Health stock. The shares were sold at an average price of $21.21, for a total transaction of $212,100.00.

EVH opened at $27.65 on Friday. The stock has a market cap of $2.06 billion, a P/E ratio of -39.50 and a beta of 1.22. Evolent Health Inc has a fifty-two week low of $10.30 and a fifty-two week high of $28.20. The company has a current ratio of 2.59, a quick ratio of 2.59 and a debt-to-equity ratio of 0.12.

Evolent Health (NYSE:EVH) last released its quarterly earnings data on Tuesday, August 7th. The technology company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.01. The firm had revenue of $144.51 million for the quarter, compared to analyst estimates of $141.90 million. Evolent Health had a negative net margin of 9.84% and a negative return on equity of 1.82%. sell-side analysts predict that Evolent Health Inc will post -0.35 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. State of Wisconsin Investment Board raised its stake in Evolent Health by 25.0% during the first quarter. State of Wisconsin Investment Board now owns 500,000 shares of the technology company’s stock worth $7,125,000 after acquiring an additional 100,000 shares during the period. Carillon Tower Advisers Inc. grew its position in Evolent Health by 72.7% in the 2nd quarter. Carillon Tower Advisers Inc. now owns 1,633,453 shares of the technology company’s stock worth $34,384,000 after purchasing an additional 687,893 shares during the last quarter. Northern Trust Corp grew its position in Evolent Health by 2.1% in the 1st quarter. Northern Trust Corp now owns 834,169 shares of the technology company’s stock worth $11,886,000 after purchasing an additional 16,912 shares during the last quarter. Cortina Asset Management LLC grew its position in Evolent Health by 10.9% in the 1st quarter. Cortina Asset Management LLC now owns 458,662 shares of the technology company’s stock worth $6,536,000 after purchasing an additional 45,256 shares during the last quarter. Finally, Standard Life Aberdeen plc grew its position in Evolent Health by 32.5% in the 2nd quarter. Standard Life Aberdeen plc now owns 1,469,650 shares of the technology company’s stock worth $30,973,000 after purchasing an additional 360,206 shares during the last quarter.

EVH has been the topic of a number of recent analyst reports. Cantor Fitzgerald restated a “buy” rating and issued a $37.00 target price on shares of Evolent Health in a research note on Wednesday. Zacks Investment Research upgraded shares of Evolent Health from a “hold” rating to a “buy” rating and set a $26.00 target price on the stock in a research note on Tuesday, July 10th. ValuEngine upgraded shares of Evolent Health from a “hold” rating to a “buy” rating in a research note on Thursday, August 9th. Jefferies Financial Group restated a “buy” rating and issued a $25.00 target price on shares of Evolent Health in a research note on Tuesday, August 7th. Finally, SunTrust Banks increased their price objective on shares of Evolent Health and gave the stock a “buy” rating in a research note on Thursday, June 7th. One analyst has rated the stock with a sell rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $28.67.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.

See Also: Moving Average (MA)

Insider Buying and Selling by Quarter for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply